Quisinostat (JNJ-26481585)是一种新型的,二代HDAC抑制剂,对HDAC作用最有效,IC50为0.11 nM,适度有效作用于HDACs 2, 4, 10,和11;比作用于HDACs 3, 5, 8,和9选择性强30倍,对HDACs 6和7作用效果最弱。
Quisinostat (JNJ-26481585) is a novel second-generation HDAC inhibitor with highest potency for HDAC1 withIC50 of 0.11 nM, modest potent to HDACs 2, 4, 10, and 11; greater than 30-fold selectivity against HDACs 3, 5, 8, and 9 and lowest potency to HDACs 6 and 7.
15% Captisol
0-300 nM
≤10 mg/kg 口服处理或腹腔注射
动物 A (mg/kg) = 动物 B (mg/kg)×动物 B的Km系数/动物 A的Km系数 | |
例如,已知某工具药用于小鼠的剂量为88 mg/kg , 则用于大鼠的剂量换算方法:将88 mg/kg 乘以小鼠的Km系数(3),再除以大鼠的Km系数(6),得到该药物用于大鼠的等效剂量44 mg/kg。
[1] Arts J, et al. Clin Cancer Res, 2009, 15(22), 6841-6851.
分子式 C21H26N6O2 |
分子量 394.47 |
CAS号 875320-29-9 |
储存方式 ﹣20 ℃冷藏长期储存。冰袋运输 |
溶剂(常温) |
DMSO 79 mg/mL |
Water <1 mg/mL |
Ethanol <1 mg/mL |
体内溶解度
NCT Number | Conditions | Interventions | Sponsor/Collaborators | Phases | Start Date | Last Updated |
NCT01486277 | Lymphoma, T-Cell, Cutaneous | Drug: Quisinostat, 12 mg | Janssen Research & Development, LLC | Phase 2 | 2011-11-01 | 2016-11-02 |
NCT02948075 | Ovarian Cancer | Drug: Quisinostat|Drug: Paclitaxel|Drug: Carboplatin | NewVac LLC|Janssen Pharmaceutica N.V., Belgium | Phase 2 | 2015-09-01 | 2016-12-14 |
NCT02728492 | Non-small Cell Lung Cancer|Epithelial Ovarian Cancer | Drug: Quisinostat|Drug: Paclitaxel|Drug: Carboplatin|Drug: Gemcitabine|Drug: Cisplatin | NewVac LLC|Janssen Pharmaceutica N.V., Belgium | Phase 1 | 2013-08-01 | 2016-05-02 |
NCT00676728 | Advanced or Refractory Leukemia|Myelodysplastic Syndromes | Drug: JNJ-26481585 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Phase 1 | 2008-12-01 | 2012-09-13 |
NCT00677105 | Lymphoma|Neoplasms | Drug: JNJ-26481585 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Janssen Pharmaceutica N.V., Belgium | Phase 1 | 2007-08-01 | 2012-09-14 |
NCT01464112 | Multiple Myeloma | Drug: JNJ-2641585 / VELCADE / Dexamethasone | Janssen Research & Development, LLC | Phase 1 | 2011-09-01 | 2016-12-30 |
注:以上所有数据均来自公开文献,并不保证对所有实验均有效,数据仅供参考。
相关化合物库
使用AMQUAR产品发表文献后请联系我们